undamentalytics Newsletter
Sign in

Marker Therapeutics, Inc. cash flow statement

In fiscal 2025, Marker Therapeutics, Inc.'s operations generated −$12.0m of cash; it spent $0 on capital projects, leaving free cash flow of −$12.0m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMMar 2026
Cash from operations−8−14−18−20−27−27−16−11−12−8
Depreciation and amortisation—00023————
Stock-based pay31655631010
Capital spending0000000000
Free cash flow−8−15−19−20−27−27−16−11−12−8
Free cash flow after stock pay−11−31−24−25−33−30−17−11−13−8
Share buybacks00————————
Shares issued——0653011510—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DBVT vs MRKRDYAI vs MRKRALGS vs MRKR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Marker Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Marker Therapeutics, Inc.